Maggie Li Selected Research

COVID-19

1/2023	Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization.
1/2023	Three doses of COVID-19 mRNA vaccine induce class-switched antibody responses in inflammatory arthritis patients on immunomodulatory therapies.
9/2022	Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization.
3/2022	High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern.
1/2022	Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine-Induced Immunity in Older Adults.
1/2022	Infection With the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Variant Is Associated With Higher Recovery of Infectious Virus Compared to the Alpha Variant in Both Unvaccinated and Vaccinated Individuals.
1/2022	Successful kidney transplantation from a deceased donor with severe COVID-19 respiratory illness with undetectable SARS-CoV-2 in donor kidney and aorta.
1/2022	Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern.
1/2022	SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levels.
1/2022	Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maggie Li Research Topics

Disease

12	COVID-19 01/2023 - 07/2021
8	Infections 01/2023 - 07/2021
3	Neoplasms (Cancer) 12/2023 - 11/2020
2	Breakthrough Infections 01/2022 - 01/2022
1	Carcinogenesis 12/2023
1	HIV Infections (HIV Infection) 11/2023
1	Virus Diseases (Viral Diseases) 10/2023
1	Arthritis (Polyarthritis) 01/2023
1	Movement Disorders (Movement Disorder) 01/2023
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 04/2022
1	Frailty 01/2022
1	Reinfection 01/2022
1	Parkinson Disease (Parkinson's Disease) 10/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 10/2021
1	Asymptomatic Infections 07/2021

Drug/Important Bio-Agent (IBA)

7	Immunoglobulin G (IgG)IBA 03/2022 - 07/2021
4	VaccinesIBA 10/2023 - 01/2022
4	Messenger RNA (mRNA)IBA 01/2023 - 07/2021
3	Viral RNAIBA 01/2022 - 07/2021
3	Antiviral Agents (Antivirals)IBA 01/2022 - 07/2021
2	N-(2-cyanoethylene)urea (BA 1)IBA 01/2023 - 09/2022
2	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2023 - 09/2022
2	Particulate MatterIBA 04/2022 - 10/2021
1	Mevalonic Acid (Mevalonate)IBA 12/2023
1	Proteins (Proteins, Gene)FDA Link 12/2023
1	CholesterolIBA 12/2023
1	Nelfinavir (Viracept)FDA Link 11/2023
1	Aspartic Acid ProteasesIBA 11/2023
1	Protease Inhibitors (Protease Inhibitor)IBA 11/2023
1	Histones (Histone)IBA 01/2023
1	mRNA VaccinesIBA 01/2023
1	Adenosine Triphosphatases (ATPase)IBA 01/2023
1	ChromatinIBA 01/2023
1	Transcription Factors (Transcription Factor)IBA 01/2023
1	Histone Acetyltransferases (Histone Acetyltransferase)IBA 01/2023
1	EpitopesIBA 01/2022
1	AntibodiesIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	AntigensIBA 11/2021
1	Phosphotransferases (Kinase)IBA 11/2020

Therapy/Procedure

1	Activities of Daily Living (ADL) 01/2023
1	Therapeutics 01/2023
1	Immunomodulation 01/2023
1	Kidney Transplantation 01/2022